| Field | Specification |
|---|---|
| Target | |
| Alternative names | General transcription and DNA repair factor IIH helicase subunit XPD; TFIIH subunit XPD; Basic transcription factor 2 80 kDa subunit; BTF2 p80; CXPD; DNA 5'-3' helicase XPD; DNA excision repair protein ERCC-2; DNA repair protein complementing XP-D cells; TFIIH basal transcription factor complex 80 kDa subunit; TFIIH 80 kDa subunit; TFIIH p80; Xeroderma pigmentosum group D-complementing protein; ERCC2; XPD; XPDC |
| UniProt # | |
| Host | |
| Clone | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | A synthesized peptide derived from human XPD |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Liquid |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
Clone 25E62 is a rabbit monoclonal antibody that recognizes general transcription and DNA repair factor IIH helicase subunit XPD (gene ERCC2) in human, mouse and rat samples and is validated for Western blot, IHC and ICC/IF. The predicted molecular weight is 86.9 kDa, and the supplier reports an observed band at about 73 kDa.
XPD (ERCC2) is an ATP-dependent 5′-3′ DNA helicase and subunit of the TFIIH complex, which functions in both RNA polymerase II transcription and nucleotide excision repair. In repair, XPD verifies damage and opens DNA around lesions. Mutations cause xeroderma pigmentosum group D, trichothiodystrophy and related disorders.
| Target | General transcription and DNA repair factor IIH helicase subunit XPD (gene ERCC2; UniProt P18074, human) |
|---|---|
| Clone | 25E62 |
| Host / Clonality / Isotype | Rabbit / Monoclonal / IgG |
| Reactivity | Human, Mouse, Rat |
| Form | Liquid |
| Formulation | PBS (pH 7.4); 150 mM NaCl; 0.02% sodium azide; 50% glycerol; plus stabilizers |
| Calculated MW | 86.9 kDa |
| Observed MW | 73 kDa |
| Storage | Long term: −20 °C for up to 12 months. Frequent use: 4 °C for up to 1 month. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 1:500–1:2000 |
|---|---|
| Immunohistochemistry | 1:50–1:200 |
| Immunocytochemistry / Immunofluorescence | 1:50–1:200 |
Samples with a confirmed band (WB): human K562 cells, human U251 cells, human SiHa cells, human HepG2 cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 10% SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 1:500 overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): human ovarian cancer tissue, human skin cancer tissue, mouse testis tissue, rat testis tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Immunogen
Synthetic peptide based on the sequence of human XPD.
Reactivity Notes
The supplier lists reactivity with human, mouse and rat. UniProt places general transcription and DNA repair factor IIH helicase subunit XPD in the nucleus and cytoplasm. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
